15 November 2018 Research: Commentary WHO Preferred Product Preferences for TB Vaccines
SATVI Director Professor Mark Hatherill has co-authored a commentary titled "WHO preferred product characteristics for new vaccines against tuberculosis" appearing in The Lancet journal.
South African Tuberculosis Vaccine Initiative, Director Professor Mark Hatherill has collaborated with fellow members of the World Health Organization (WHO) Tuberculosis Vaccine Advisory Group; Lewis K Schrager, Padmapriyadarsini Chandrasekaran, Bernard H Fritzell, Paul-Henri Lambert, Helen McShane, Nadia Tornieporth and Johan Vekemans providing a commentary on the World Health Organization (WHO) Preferred Product Characteristics for Tuberculosis vaccines which were adopted earlier this year.
The World Health Organization (WHO) preferred product characteristics (PPCs) provide guidance to scientists, regulators, funding agencies, and industry groups developing tuberculosis vaccine candidates intended for WHO prequalification.
WHO presented two sets of PPC's for tuberculosis vaccines, one guiding the development of vaccines for adolescents and adults, the other addressing vaccine development for neonates and infants.
|Read the World Health Organization (WHO) Preferred Product Characteristics for Tuberculosis Vaccines|